VET4 H1
Alternative Names: VET4-H1Latest Information Update: 12 Nov 2021
At a glance
- Originator KaliVir Immunotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; High mobility group protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 12 Nov 2021 KaliVir Immunotherapeutics has two US patents relating to two separate licensed technologies which support VET™ platform
- 24 Mar 2021 VET4 H1 is available for licensing as of 10 Dec 2020. https://kalivir.com/#pipeline
- 10 Dec 2020 Early research in Solid tumours in USA (IV) before December 2020 (KaliVir Immunotherapeutics pipeline, December 2020)